Stunning clinical trial results with chimeric antigen receptor (CAR)-T cell-based therapies and virus-based gene therapies, and approvals of the first pioneering medicines in these categories, have given a boost to the hundreds of biotech companies working in the sector, and led to concerns about how contract manufacturing organizations and other third-party manufacturing suites will be able to meet the burgeoning demand for their services.
"There's a real lack of manufacturing capacity for cell therapy companies, and they are block-booking suites in CMOs even if...
